Dr. Mehta on the Current Treatment Paradigm in HER2-Positive Gastric Cancer

Video

In Partnership With:

Rutika J. Mehta, MD, MPH, discusses the ​current treatment paradigm in HER2-positive gastric cancer. 

Rutika J. Mehta, MD, MPH, a medical oncologist specializing in gastrointestinal cancer at Moffitt Cancer Center, discusses the ​current treatment paradigm in HER2-positive gastric cancer. 

Unlike the HER2-positive breast cancer space, patients with HER2-positive gastric cancer have limited treatment options, says Mehta.

Moreover, since there are no data supporting the continuation of ​trastuzumab (Herceptin) after disease progression, the field is ​working to​ identify the mechanism of resistance to trastuzumab, Mehta explains. 

Additionally, HER2-positive gastric cancer tends to be more heterogeneous compared with HER2-positive breast cancer, which poses the question of whether lesion-specific biopsies are representative of the entire disease. As such, the optimal role of trastuzumab and other anti–HER2-based regimens remain largely unknown in this space, Mehta concludes.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine